Efficacy and safety of ciprofol for gastroscopy in patients with obesity: a randomised clinical controlled trial using different weight-based dosing scales.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968535 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2253 (Electronic) Linking ISSN: 14712253 NLM ISO Abbreviation: BMC Anesthesiol Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2001-

Gastroscopy*/methods ; Obesity* ; Body Weight*; Humans ; Female ; Adult ; Male ; Middle Aged ; Prospective Studies ; Young Adult ; Aged ; Adolescent ; Dose-Response Relationship, Drug ; Body Mass Index ; Cyclopropanes

Competing Interests: Declarations. Ethics approval and consent to participate: Ethical approval was obtained from the Medical Ethics Committee of Shunde Hospital of Southern Medical University (approval no. KYLS20230624). This study was conducted in accordance with the 1964 Declaration of Helsinki and its amendments. Written informed consent was obtained from all the participants or their families before initiating any study-related activities. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Background: This study aimed to compare the efficacy and safety of ciprofol-induced doses based on three indices: total body weight (TBW), ideal body weight (IBW), and lean body weight (LBW) in patients with obesity undergoing gastroscopy.
Methods: In a single-centre, prospective, randomised study conducted at an endoscopy centre, a total of 108 patients aged 18-65 years who underwent painless gastroscopy and had a body mass index (BMI) of 28-39.9 kg/m ² were included. Patients with obesity from the intended study population were randomised to receive a ciprofol infusion (0.4 mg/kg) for the induction of anaesthesia based on TBW (Group T), IBW (Group I), or LBW (Group L). A Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale score of < 1 was considered a marker of loss of consciousness, prompting gastroscopy. The primary outcomes were the success rate of anaesthesia for the procedures, and that of general anaesthesia achieved using the initial dose. Secondary outcomes included the frequency of remedial sedation, total ciprofol dose, and adverse events RESULTS: The procedure success rate was 100% in all three groups. Compared to Group L, the general anaesthesia success rate achieved with the initial dose was higher and the frequency of remedial sedation was lower in Groups T and I. Compared to Group L, fewer patients in Group T required additional medication. Compared to Group T, the occurrence of hypoxaemia was lower in the remaining two groups, and Group L had a lower incidence of posterior tongue drops and hypotension.
Conclusions: Induction doses of ciprofol based on TBW or IBW provided better anaesthesia than doses based on LBW for gastroscopy in patients with obesity. LBW-based induction doses of ciprofol improved cardiovascular stability and respiratory safety, whereas IBW-based induction doses of ciprofol reduced respiratory depression.
Trial Registration: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2300073539 first registration date 13/07/2023).
(© 2025. The Author(s).)

Br J Anaesth. 2007 Jan;98(1):66-75. (PMID: 17132644)
BMC Anesthesiol. 2022 Apr 5;22(1):98. (PMID: 35382771)
Can J Anaesth. 2017 May;64(5):471-479. (PMID: 28243855)
Eur J Anaesthesiol. 2023 Jun 1;40(6):399-406. (PMID: 36647565)
Eur J Anaesthesiol. 2009 May;26(5):359-61. (PMID: 19359991)
Clin Drug Investig. 2018 Aug;38(8):673-693. (PMID: 29855999)
Diabetes Obes Metab. 2023 Nov;25(11):3390-3399. (PMID: 37589256)
Br J Anaesth. 2022 Apr;128(4):610-622. (PMID: 34916051)
Gastrointest Endosc. 2015 Sep;82(3):503-11. (PMID: 25851159)
World J Clin Cases. 2021 Jul 16;9(20):5479-5489. (PMID: 34307602)
Anesth Analg. 2021 Jan;132(1):53-64. (PMID: 32282384)
Curr Opin Anaesthesiol. 2018 Dec;31(6):693-699. (PMID: 30379735)
Korean J Anesthesiol. 2021 Dec;74(6):478-487. (PMID: 34407372)
Eur J Anaesthesiol. 2010 Jun;27(6):572-4. (PMID: 20308907)
Anesth Analg. 2011 Jul;113(1):57-62. (PMID: 20861415)
Plast Reconstr Surg Glob Open. 2022 Dec 07;10(12):e4697. (PMID: 36518689)
Curr Opin Crit Care. 2018 Dec;24(6):560-567. (PMID: 30299311)
Intest Res. 2017 Oct;15(4):456-466. (PMID: 29142513)
J Clin Psychopharmacol. 1990 Aug;10(4):244-51. (PMID: 2286697)
Anaesthesia. 2023 Jan;78(1):81-92. (PMID: 36044543)
J Trauma Nurs. 2014 Jan-Feb;21(1):4-8. (PMID: 24399312)
Crit Care Med. 2023 Oct 1;51(10):1318-1327. (PMID: 37272947)
BMJ Open. 2023 Dec 28;13(12):e079095. (PMID: 38154891)
J Clin Anesth. 1995 Feb;7(1):89-91. (PMID: 7772368)
Anaesth Crit Care Pain Med. 2020 Apr;39(2):229-238. (PMID: 32068132)
N Engl J Med. 2017 Oct 12;377(15):1496. (PMID: 29020585)
Pharm Res. 2009 Jul;26(7):1626-34. (PMID: 19337821)
Biomed Pharmacother. 2018 Oct;106:618-623. (PMID: 29990851)
BMJ Open. 2023 May 31;13(5):e071438. (PMID: 37258073)
Drug Metab Dispos. 2016 Oct;44(10):1579-83. (PMID: 27481855)
Crit Care. 2020 Jun 8;24(1):315. (PMID: 32513237)
Braz J Med Biol Res. 2022 Oct 03;55:e12331. (PMID: 36197415)
Can J Anaesth. 2017 May;64(5):449-455. (PMID: 28247242)
Basic Clin Pharmacol Toxicol. 2022 Aug;131(2):138-148. (PMID: 35653554)
J Clin Anesth. 2023 May;85:111047. (PMID: 36599219)
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):699-714. (PMID: 30323319)
Br J Anaesth. 2015 Jul;115(1):141-2. (PMID: 26089463)
Pharmacotherapy. 2012 Sep;32(9):856-68. (PMID: 22711238)
Pharmacol Res Perspect. 2023 Apr;11(2):e01066. (PMID: 36811327)
Biomed Res Int. 2023 Jan 19;2023:7443226. (PMID: 36714027)
Obes Surg. 2017 Jun;27(6):1501-1507. (PMID: 27885537)

SRSP2021039 the 2021 Key Specialist Project of Clinical Medicine, Shunde Hospital of Southern Medical University (Cultivation Project); 2023ZDZX2008 the 2023 Key Scientific Research Platforms and Projects of Ordinary Universities in Guangdong Province; 2023A1515140142 the 2023 Basic and Applied Basic Research Joint Fund in Guangdong Province (Guangdong-Foshan)

Keywords: Ciprofol; Gastroscopy; Obesity; Weight-based scalars

0 ((2-(1R)-1-cyclopropyl)ethyl-6-isopropyl-phenol)
0 (Cyclopropanes)

Date Created: 20250302 Date Completed: 20250303 Latest Revision: 20250510

20250511

PMC11874440

10.1186/s12871-025-02974-7

40025458